Description: Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: Response, Progression, and Pseudoprogression

This title appears in the Scientific Report : 2020

Imaging challenges of immunotherapy and targeted therapy in patients with brain metastases: Response, Progression, and Pseudoprogression

The advent of immunotherapy using immune checkpoint inhibitors (ICIs) and targeted therapy (TT) has dramatically improved the prognosis of various cancer types. However, following ICI therapy or TT—either alone (especially ICI) or in combination with radiotherapy—imaging findings on anatomical contr...

Personal Name(s):	Galldiks, Norbert (Corresponding author)
	Kocher, Martin / Ceccon, Garry / Werner, Jan-Michael / Brunn, Anna / Deckert, Martina / Pope, Whitney B / Soffietti, Riccardo / Le Rhun, Emilie / Weller, Michael / Tonn, Jörg C / Fink, Gereon R / Langen, Karl-Josef
Contributing Institute:	Physik der Medizinischen Bildgebung; INM-4 Kognitive Neurowissenschaften; INM-3
Published in:	Neuro-Oncology, 22 (2020) 1, S. 17-30
Imprint:	Oxford Oxford Univ. Press 2020
PubMed ID:	31437274
DOI:	10.1093/neuonc/noz147
Document Type:	Journal Article
Research Program:	(Dys-)function and Plasticity
Link:	Get full text Restricted Get full text Published on 2019-08-22. Available in OpenAccess from 2020-08-22. Published on 2019-08-22. Available in OpenAccess from 2020-08-22. Restricted
	Publikationsportal JuSER

Please use the identifier: http://hdl.handle.net/2128/23923 in citations.
Please use the identifier: http://dx.doi.org/10.1093/neuonc/noz147 in citations.

The advent of immunotherapy using immune checkpoint inhibitors (ICIs) and targeted therapy (TT) has dramatically improved the prognosis of various cancer types. However, following ICI therapy or TT—either alone (especially ICI) or in combination with radiotherapy—imaging findings on anatomical contrast-enhanced MRI can be unpredictable and highly variable, and are often difficult to interpret regarding treatment response and outcome. This review aims at summarizing the imaging challenges related to TT and ICI monotherapy as well as combined with radiotherapy in patients with brain metastases, and to give an overview on advanced imaging techniques which potentially overcome some of these imaging challenges. Currently, major evidence suggests that imaging parameters especially derived from amino acid PET, perfusion-/diffusion-weighted MRI, or MR spectroscopy may provide valuable additional information for the differentiation of treatment-induced changes from brain metastases recurrence and the evaluation of treatment response.